Ireland
--:--IST
Recruiting Observational

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

NCT05185492 · tracked via the Priya Life Science Canada tracker
Sponsor
STAVROS G DRAKOS
Phase
Observational
Started
2022-05-25
Last updated
2026-03-20

Condition(s) studied

Cardiogenic ShockAcute Myocardial Infarction

Study summary

This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term outcomes of all Cardiogenic Shock (CS) patients cared for at four high volume dedicated shock care centers. As the first true North American multicenter CS collaborative with a uniform dedicated and comprehensive case report form, the high patient volumes and wide spectrum of clinical acuity seen at these institutions will provide valuable insight into the factors associated with adverse outcomes; and will serve as a blueprint for future clinical trial designs that may better inform clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes * Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry Exclusion Criteria: * Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.

Primary outcome measure(s)

  • Survival — 1 year
    Percentage of participants alive at analysis time points

Trial sites (3)

FacilityCityRegionStatus
Cleveland Clinic Florida Weston Florida Recruiting
Inova Heart and Vascular Institute Falls Church Virginia Recruiting
University of Toronto Toronto Ontario Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05185492 on ClinicalTrials.gov ↗ ← All trials in Canada